Age: 46.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Angina pectoris, Blood test, Fear, Pleuritic pain, X-ray
Clinical narrative: I was scared that maybe it's cardiac.; I started feeling 'disc' pain in my left pleural area around my heart more towards my lung; Now the pain resumed again/I was scared that maybe it's cardiac.; This is a spontaneous report received from a contactable nurse (patient herself). A 46-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Lot Number: EW0181, expiry date: unknown, Age at Vaccination: 46 years), via an unspecified route of administration, administered in Arm Left on 06Aug2021 as dose 1, single for COVID-19 immunization. The patient's medical history included Blood cholesterol increased. Patient did not have diabetes, did not have hypertension. Concomitant medications included Rosuvastatin (20mg) for High cholesterol and Cyclobenzaprine (10mg). It was reported that, she did not have any vaccination 4 weeks prior to COVID 19 Vaccine and not taken any other medications within 4 weeks. On 07Aug2021, it was reported that, the patient started feeling disc pain in her left pleural area around her heart more towards her lung. Patient just could not describe it, but started feeling the pain and so took some pain pills (treatment). Patient slept and woke up and felt like okay it was minimum then it was before. So, didn't rush to say let me go to hospital or anything. Now, the next day like well it just started just collecting, now patient sleeps and it doesn't been go away (further clarification unknown). So, ended up in the like ED on 15Aug2021 because was scared that maybe it was cardiac. So, went to the ED, they did x-ray, they drew blood, they did D-dimer all on 15Aug2021 to check for clot, they did a couple of other things and the nurse practitioner came back to tell that they were all negative, they didn't find any particulate in x-rays, in the blood, they checked for clot, they didn't find anything. So, she advised to follow-up with primary healthcare doctor and they gave IV Ketorolac (treatment) and immediately and felt a relief. So, came back home. Now, afterwards, though they gave me the prescription for Ketorolac and Cyclobenzaprine which I have been taking. So, I work night shift and the Cyclobenzaprine made very sleepy. So, didn't take it in one of the night that I don't, I have to work. Now the pain resumed again on an unspecified date in Aug2021 (further clarification unknown) and yesterday was second shot. So, when patient went to the health department told them that this is the situation so the first one patient got it on my left so said okay this time put it on right and then make sure that it's not, do not take same side again. So, she put it on my right. So, of course I am having tenderness and the pain at the injection site but I don't feel the pain that is in my left area I don't feel like in my right side. So, it was the lady who gave the injection yesterday when told her what patient was going through she is like why didn't the lady give you as in yeah, she didn't gave me anything. So, she gave me the brochure with the Pfizer number and said yeah, call this number and let them know whatever happened. I said okay because I didn't know yeah, so that is what happened and right yeah this morning I was in so much pain. Therapeutic measures were taken as a result of events like some pain pills and IV Ketorolac (10mg). Consumer stated, yes, because she never had any pain in her body until she got it, when asked about causality. The outcome of the events was unknown.   No follow-up attempts possible. No further information expected.; Sender's Comments: Based on the information in the case report and a plausible temporal relationship,  a possible causal relationship between the events Pleuritic pain and Cardiac pain and suspect drug BNT162B2 cannot be excluded.   The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.